Who is sponsoring NCT00346086?

NCT00346086 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT00346086?

Interventions in NCT00346086: AIC (Amb a 1 Immunostimulatory Conjugate).

What condition does NCT00346086 study?

NCT00346086 studies Seasonal Allergic Rhinitis.

Is NCT00346086 still recruiting?

NCT00346086 is currently completed. Last updated 13 December 2018.

Last reviewed 2018-12-13 · How we verify

NCT00346086

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DNA Vaccine for Ragweed Allergic Adults

Completed Phase 2 Last updated 13 December 2018

What this trial tests

Phase 2 trial testing AIC (Amb a 1 Immunostimulatory Conjugate) in Seasonal Allergic Rhinitis in 25 participants. Completed in 21 August 2001.

Timeline

18 May 2001

Primary endpoint
21 August 2001

21 August 2001

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	18 May 2001
Primary completion	21 August 2001
Estimated completion	21 August 2001
Sites	1 location across United States

Drugs / interventions tested

AIC (Amb a 1 Immunostimulatory Conjugate) — full drug profile →

Conditions studied

Seasonal Allergic Rhinitis — all drugs for Seasonal Allergic Rhinitis →

Sponsor

Johns Hopkins University

Who can join

Adults 18 to 60, any sex, with Seasonal Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity and immunogenicity have either decreased, or increased in tandem, with no resultant efficacy: safety benefit ratio. This study utilizes an adjuvant approach in which synthetic immunostimulatory DNA is conjugated to ragweed allergen in an attempt to modulate both the clinical and immunologic allergic response to ragweed exposure in ragweed-allergic patients with seasonal rhinitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.
Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, et al · · 2006 · cited 370× · PMID 17021320 · DOI 10.1056/nejmoa052916
CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance.
Montamat G, Leonard C, Poli A, Klimek L, et al · · 2021 · cited 32× · PMID 33708195 · DOI 10.3389/fimmu.2021.590054
Activation of Innate Immunity by Therapeutic Nucleic Acids.
Bishani A, Chernolovskaya EL. · · 2021 · cited 26× · PMID 34948156 · DOI 10.3390/ijms222413360

Verify or expand the search:

Other recruiting trials for Seasonal Allergic Rhinitis

Currently open trials in the same condition.

NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
NCT07291284 — Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis · Phase 3 · active not recruiting
NCT06300203 — Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis · Phase 2 · recruiting
NCT04815668 — Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis · NA · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00346086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 13 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00346086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing